The role of the aromatic hydrocarbon receptor in the pathogenesis of atopic dermatitis

Cover Page

Cite item

Full Text

Abstract

The aromatic hydrocarbon receptor (AhR) is a cytoplasmic receptor and transcription factor that regulates a wide range of biological and toxicological effects by binding to specific ligands. Among the effects there is detoxification of xenobiotics, maintenance of tissue homeostasis, regulation of the immune response. The structure and functions of AhR are described in the review. The mechanisms of skin homeostasis with the participation of the aromatic hydrocarbon receptor such as the effect on oxidative reactions and participation in maintaining the barrier function of the epidermis are demonstrated in details. The role of AhR in the pathogenesis of atopic dermatitis is discussed. The participation of AhR in the implementation of immune mechanisms of this disease as well as in the regulation of the production of key proteins of the skin barrier is shown. The data on the therapeutic value of its pharmacological modulation including the results of clinical studies of the topical ligand AhR Tapinarof are presented. The role of the aromatic hydrocarbon receptor in the realization of the effect of phototherapy of atopic dermatitis is demonstrated.

About the authors

Pavel V. Gorodnichev

Nizhny Novgorod Branch of the State Research Center of Dermatovenereology and Cosmetology

Author for correspondence.
Email: gorpav@icloud.com
ORCID iD: 0000-0001-5989-7156
SPIN-code: 6103-0456
Russian Federation, Nizhny Novgorod

References

  1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X
  2. Silverberg JI. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clin. 2017;35(3):283–289. doi: 10.1016/j.det.2017.02.002
  3. Кубанов А. А., Богданова Е. В. Результаты деятельности медицинских организаций, оказывающих медицинскую помощь по профилю «дерматовенерология», в 2019–2021 гг. в Российской Федерации. Вестник дерматологии и венерологии. 2022; 98(5):18–33 [Kubanov AA, Bogdanova EV. Performance results of medical organizations providing medical care in the field of dermatovenereology in 2019–2021 in the Russian Federation. Vestnik dermatologii i venerologii. 2022;98(5):18–33. (In Russ.)] doi: 10.25208/vdv1337
  4. Igarashi A, Fujita H, Arima K, Inoue T, Dorey J, Fukushima A, et al. Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis. J Dermatol. 2019;46(8):652–661. doi: 10.1111/1346-8138.14947
  5. Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Pathogenesis of Atopic Dermatitis: Current Paradigm. Iran J Immunol. 2019;16(2):97–107. doi: 10.22034/IJI.2019.80253
  6. Furue K, Mitoma C, Tsuji G, Furue M. Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation. Immunobiology. 2018;223(3):327–330. doi: 10.1016/j.imbio.2017.10.047
  7. Furue M, Hashimoto-Hachiya A, Tsuji G. Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis. Acta Derm Venereol. 2018;98(10):918–923. doi: 10.2340/00015555-3003
  8. Furue M, Takahara M, Nakahara T, Uchi H. Role of AhR/ARNT system in skin homeostasis. Arch Dermatol Res. 2014;306(9):769–779. doi: 10.1007/s00403-014-1481-7
  9. van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems IM, Hato SV, van der Valk PG, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123(2):917–927. doi: 10.1172/JCI65642
  10. Furue M, Tsuji G, Mitoma C, Nakahara T, Chiba T, Morino-Koga S, Uchi H. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80(2):83–88. doi: 10.1016/j.jdermsci.2015.07.011
  11. Fritsche E, Schäfer C, Calles C, Bernsmann T, Bernshausen T, Wurm M, et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A. 2007;104(21):8851–8856. doi: 10.1073/pnas.0701764104
  12. Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol. 2013;133(8):2023–2030. doi: 10.1038/jid.2013.92
  13. Yu J, Luo Y, Zhu Z, Zhou Y, Sun L, Gao J, et al. A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor. J Allergy Clin Immunol. 2019;143(6):2108–2119.e12. doi: 10.1016/j.jaci.2018.11.036
  14. Kiyomatsu-Oda M, Uchi H, Morino-Koga S, Furue M. Protective role of 6-formylindolo[3,2-b]carbazole (FICZ), an endogenous ligand for arylhydrocarbon receptor, in chronic mite-induced dermatitis. J Dermatol Sci. 2018;90(3):284–294. doi: 10.1016/j.jdermsci.2018.02.014
  15. Nebert DW. Aryl hydrocarbon receptor (AHR): "pioneer member" of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of "sensors" of foreign and endogenous signals. Prog Lipid Res. 2017;67:38–57. doi: 10.1016/j.plipres.2017.06.001
  16. Swanson HI. DNA binding and protein interactions of the AHR/ARNT heterodimer that facilitate gene activation. Chem Biol Interact. 2002;141(1-2):63–76. doi: 10.1016/s0009-2797(02)00066-2
  17. Seok SH, Lee W, Jiang L, Molugu K, Zheng A, Li Y, et al. Structural hierarchy controlling dimerization and target DNA recognition in the AHR transcriptional complex. Proc Natl Acad Sci U S A. 2017;114(21):5431–5436. doi: 10.1073/pnas.1617035114
  18. Corrada D, Denison MS, Bonati L. Structural modeling of the AhR:ARNT complex in the bHLH-PASA-PASB region elucidates the key determinants of dimerization. Mol Biosyst. 2017;13(5):981–990. doi: 10.1039/c7mb00005g
  19. Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology. 2009;127(3):299–311. doi: 10.1111/j.1365-2567.2009.03054.x
  20. Esser C, Bargen I, Weighardt H, Haarmann-Stemmann T, Krutmann J. Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol. 2013;35(6):677–691. doi: 10.1007/s00281-013-0394-4
  21. Furue M, Fuyuno Y, Mitoma C, Uchi H, Tsuji G. Therapeutic agents with AHR inhibiting and NRF2 activating activity for managing chloracne. Antioxidants (Basel). 2018;7(7):90. doi: 10.3390/antiox7070090
  22. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta. 2003;1619(3):263–268. doi: 10.1016/s0304-4165(02)00485-3
  23. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr. 2008;18(3):207–250. doi: 10.1615/critreveukargeneexpr.v18.i3.20
  24. Esser C, Rannug A. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev. 2015;67(2):259–279. doi: 10.1124/pr.114.009001
  25. Poland A, Glover E, Kende AS. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem. 1976;251(16):4936–4946.
  26. Tian J, Feng Y, Fu H, Xie HQ, Jiang JX, Zhao B. The Aryl Hydrocarbon Receptor: A Key Bridging Molecule of External and Internal Chemical Signals. Environ Sci Technol. 2015;49(16):9518–9531. doi: 10.1021/acs.est.5b00385
  27. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43:309–334. doi: 10.1146/annurev.pharmtox.43.100901.135828
  28. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2008;21(1):102–116. doi: 10.1021/tx7001965
  29. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci. 2011;124(1):1–22. doi: 10.1093/toxsci/kfr218
  30. Carreira VS, Fan Y, Kurita H, Wang Q, Ko CI, Naticchioni M, et al. Disruption of Ah Receptor Signaling during Mouse Development Leads to Abnormal Cardiac Structure and Function in the Adult. PLoS One. 2015;10(11):e0142440. doi: 10.1371/journal.pone.0142440
  31. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–432. doi: 10.1146/annurev-immunol-032713-120245
  32. Fujii-Kuriyama Y, Kawajiri K. Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(1):40–53. doi: 10.2183/pjab.86.40
  33. Furue M, Uchi H, Mitoma C, Hashimoto-Hachiya A, Chiba T, Ito T, et al. Antioxidants for Healthy Skin: The Emerging Role of Aryl Hydrocarbon Receptors and Nuclear Factor-Erythroid 2-Related Factor-2. Nutrients. 2017;9(3):223. doi: 10.3390/nu9030223
  34. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 1999;13(1):20–25. doi: 10.1101/gad.13.1.20
  35. Baron JM, Höller D, Schiffer R, Frankenberg S, Neis M, Merk HF, et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001;116(4):541–548. doi: 10.1046/j.1523-1747.2001.01298.x
  36. Kopf PG, Walker MK. 2,3,7,8-tetrachlorodibenzo-p-dioxin increases reactive oxygen species production in human endothelial cells via induction of cytochrome P4501A1. Toxicol Appl Pharmacol. 2010;245(1):91–99. doi: 10.1016/j.taap.2010.02.007
  37. Tanaka Y, Uchi H, Hashimoto-Hachiya A, Furue M. Tryptophan Photoproduct FICZ Upregulates IL1A, IL1B, and IL6 Expression via Oxidative Stress in Keratinocytes. Oxid Med Cell Longev. 2018;2018:9298052. doi: 10.1155/2018/9298052
  38. Tsuji G, Takahara M, Uchi H, Takeuchi S, Mitoma C, Moroi Y, et al. An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway. J Dermatol Sci. 2011;62(1):42–49. doi: 10.1016/j.jdermsci.2010.10.017
  39. Nakahara T, Mitoma C, Hashimoto-Hachiya A, Takahara M, Tsuji G, Uchi H, et al. Antioxidant Opuntia ficus-indica Extract Activates AHR-NRF2 Signaling and Upregulates Filaggrin and Loricrin Expression in Human Keratinocytes. J Med Food. 2015;18(10):1143–1149. doi: 10.1089/jmf.2014.3396
  40. Tsuji G, Takahara M, Uchi H, Matsuda T, Chiba T, Takeuchi S, et al. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflammatory effect. J Invest Dermatol. 2012;132(1):59–68. doi: 10.1038/jid.2011.194
  41. Yeager RL, Reisman SA, Aleksunes LM, Klaassen CD. Introducing the "TCDD-inducible AhR-Nrf2 gene battery". Toxicol Sci. 2009;111(2):238–246. doi: 10.1093/toxsci/kfp115
  42. Takei K, Hashimoto-Hachiya A, Takahara M, Tsuji G, Nakahara T, Furue M. Cynaropicrin attenuates UVB-induced oxidative stress via the AhR-Nrf2-Nqo1 pathway. Toxicol Lett. 2015;234(2):74–80. doi: 10.1016/j.toxlet.2015.02.007
  43. Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the 'fused genes' family. Exp Dermatol. 2012;21(9):643–649. doi: 10.1111/j.1600-0625.2012.01472.x
  44. Loertscher JA, Sattler CA, Allen-Hoffmann BL. 2,3,7,8-Tetrachlo-rodibenzo-p-dioxin alters the differentiation pattern of human keratinocytes in organotypic culture. Toxicol Appl Pharmacol. 2001;175(2):121–129. doi: 10.1006/taap.2001.9202
  45. Loertscher JA, Lin TM, Peterson RE, Allen-Hoffmann BL. In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes accelerated terminal differentiation in fetal mouse skin. Toxicol Sci. 2002;68(2):465–472. doi: 10.1093/toxsci/68.2.465
  46. Kennedy LH, Sutter CH, Leon Carrion S, Tran QT, Bodreddigari S, Kensicki E, et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated production of reactive oxygen species is an essential step in the mechanism of action to accelerate human keratinocyte differentiation. Toxicol Sci. 2013;132(1):235–249. doi: 10.1093/toxsci/kfs325
  47. van den Bogaard EH, Podolsky MA, Smits JP, Cui X, John C, Gowda K, et al. Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation. J Invest Dermatol. 2015;135(5):1320–1328. doi: 10.1038/jid.2015.6
  48. Takei K, Mitoma C, Hashimoto-Hachiya A, Takahara M, Tsuji G, Nakahara T, et al. Galactomyces fermentation filtrate prevents T helper 2-mediated reduction of filaggrin in an aryl hydrocarbon receptor-dependent manner. Clin Exp Dermatol. 2015;40(7):786–793. doi: 10.1111/ced.12635
  49. Furue M, Hashimoto-Hachiya A, Tsuji G. Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis. Acta Derm Venereol. 2018;98(10):918–923. doi: 10.2340/00015555-3003
  50. Hashimoto-Hachiya A, Tsuji G, Murai M, Yan X, Furue M. Upregulation of FLG, LOR, and IVL Expression by Rhodiola crenulata Root Extract via Aryl Hydrocarbon Receptor: Differential Involvement of OVOL1. Int J Mol Sci. 2018;19(6):1654. doi: 10.3390/ijms19061654
  51. Jin UH, Karki K, Kim SB, Safe S. Inhibition of pancreatic cancer Panc1 cell migration by omeprazole is dependent on aryl hydrocarbon receptor activation of JNK. Biochem Biophys Res Commun. 2018;501(3):751–757. doi: 10.1016/j.bbrc.2018.05.061
  52. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449–1456. doi: 10.1038/ng.3424
  53. Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi: 10.1038/jid.2008.88
  54. Cascella R, Foti Cuzzola V, Lepre T, Galli E, Moschese V, Chini L, et al. Full sequencing of the FLG gene in Italian patients with atopic eczema: evidence of new mutations, but lack of an association. J Invest Dermatol. 2011;131(4):982–984. doi: 10.1038/jid.2010.398
  55. Thawer-Esmail F, Jakasa I, Todd G, Wen Y, Brown SJ, Kroboth K, et al. South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin. J Allergy Clin Immunol. 2014;133(1):280–282.e1–2. doi: 10.1016/j.jaci.2013.09.053
  56. Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi: 10.1016/j.alit.2016.12.002
  57. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031
  58. Takei K, Mitoma C, Hashimoto-Hachiya A, Uchi H, Takahara M, Tsuji G, et al. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor. J Dermatol. 2015;42(2):171–180. doi: 10.1111/1346-8138.12717
  59. Jurakic Toncic R, Kezic S, Jakasa I, Ljubojevic Hadzavdic S, Balic A, Petkovic M, et al. Filaggrin loss-of-function mutations and levels of filaggrin degradation products in adult patients with atopic dermatitis in Croatia. J Eur Acad Dermatol Venereol. 2020;34(8):1789–1794. doi: 10.1111/jdv.16232
  60. Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, et al. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019;158(4):281–286. doi: 10.1111/imm.13120
  61. Trzeciak M, Sakowicz-Burkiewicz M, Wesserling M, Dobaczewska D, Gleń J, Nowicki R, et al. Expression of Cornified Envelope Proteins in Skin and Its Relationship with Atopic Dermatitis Phenotype. Acta Derm Venereol. 2017;97(1):36–41. doi: 10.2340/00015555-2482
  62. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: 10.1016/j.jaci.2015.03.051
  63. Flohr C, England K, Radulovic S, McLean WH, Campbel LE, Barker J, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163(6):1333–1336. doi: 10.1111/j.1365-2133.2010.10068.x
  64. Furue M, Iida K, Imaji M, Nakahara T. Microbiome analysis of forehead skin in patients with atopic dermatitis and healthy subjects: Implication of Staphylococcus and Corynebacterium. J Dermatol. 2018;45(7):876-877. doi: 10.1111/1346-8138.14486
  65. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–1160. doi: 10.1056/NEJMoa021481
  66. Nakagawa S, Matsumoto M, Katayama Y, Oguma R, Wakabayashi S, Nygaard T, et al. Staphylococcus aureus Virulent PSMα Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation. Cell Host Microbe. 2017;22(5):667–677.e5. doi: 10.1016/j.chom.2017.10.008
  67. Sugaya M. The Role of Th17-Related Cytokines in Atopic Dermatitis. Int J Mol Sci. 2020;21(4):1314. doi: 10.3390/ijms21041314
  68. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264. doi: 10.1016/j.jaci.2015.08.015
  69. Mulcahy ME, Leech JM, Renauld JC, Mills KH, McLoughlin RM. Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa. Mucosal Immunol. 2016;9(6):1429–1441. doi: 10.1038/mi.2016.24
  70. Lee E, Min K, Ahn H, Jeon BN, Park S, Yun C, et al. Potential Therapeutic Skin Microbiomes Suppressing Staphylococcus aureus-Derived Immune Responses and Upregulating Skin Barrier Function-Related Genes via the AhR Signaling Pathway. Int J Mol Sci. 2022;23(17):9551. doi: 10.3390/ijms23179551
  71. Li ZZ, Zhong WL, Hu H, Chen XF, Zhang W, Huang HY, et al. Aryl hydrocarbon receptor polymorphisms are associated with dry skin phenotypes in Chinese patients with atopic dermatitis. Clin Exp Dermatol. 2019;44(6):613–619. doi: 10.1111/ced.13841
  72. Li D, Takao T, Tsunematsu R, Morokuma S, Fukushima K, Kobayashi H, et al. Inhibition of AHR transcription by NF1C is affected by a single-nucleotide polymorphism, and is involved in suppression of human uterine endometrial cancer. Oncogene. 2013;32(41):4950–4959. doi: 10.1038/onc.2012.509
  73. Liu G, Asanoma K, Takao T, Tsukimori K, Uchi H, Furue M, et al. Aryl hydrocarbon receptor SNP -130 C/T associates with dioxins susceptibility through regulating its receptor activity and downstream effectors including interleukin 24. Toxicol Lett. 2015;232(2):384–392. doi: 10.1016/j.toxlet.2014.11.025
  74. Hong CH, Lee CH, Yu HS, Huang SK. Benzopyrene, a major polyaromatic hydrocarbon in smoke fume, mobilizes Langerhans cells and polarizes Th2/17 responses in epicutaneous protein sensitization through the aryl hydrocarbon receptor. Int Immunopharmacol. 2016;36:111–117. doi: 10.1016/j.intimp.2016.04.017
  75. Kim HO, Kim JH, Chung BY, Choi MG, Park CW. Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. Exp Dermatol. 2014;23(4):278–281. doi: 10.1111/exd.12350
  76. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res. 2005;571(1-2):185–205. doi: 10.1016/j.mrfmmm.2004.06.059
  77. Johnson-Huang LM, Suárez-Fariñas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130(11):2654–2663. doi: 10.1038/jid.2010.166
  78. Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis. Expert Rev Clin Immunol. 2019;15(11):1205–1214. doi: 10.1080/1744666X.2020.1672537
  79. Walterscheid JP, Nghiem DX, Kazimi N, Nutt LK, McConkey DJ, Norval M, et al. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci U S A. 2006;103(46):17420–17425. doi: 10.1073/pnas.0603119103
  80. Memari B, Nguyen-Yamamoto L, Salehi-Tabar R, Zago M, Fritz JH, Baglole CJ, et al. Endocrine aryl hydrocarbon receptor signaling is induced by moderate cutaneous exposure to ultraviolet light. Sci Rep. 2019;9(1):8486. doi: 10.1038/s41598-019-44862-4
  81. Paine AJ. Induction of benzo[a]pyrene Mono-oxygenase in liver cell culture by the photochemical generation of active oxygen species. Evidence for the involvement of singlet oxygen and the formation of a stable inducing intermediate. Biochem J. 1976;158(1):109–117. doi: 10.1042/bj1580109
  82. Schallreuter KU, Salem MA, Gibbons NC, Maitland DJ, Marsch E, Elwary SM, et al. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: Epidermal H2O2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling. FASEB J. 2012;26(6):2471–2485. doi: 10.1096/fj.11-201897
  83. Wincent E, Amini N, Luecke S, Glatt H, Bergman J, Crescenzi C, et al. The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo[3,2-b]carbazole is present in humans. J Biol Chem. 2009;284(5):2690–2696. doi: 10.1074/jbc.M808321200
  84. Tigges J, Haarmann-Stemmann T, Vogel CFA, Grindel A, Hübenthal U, Brenden H, et al. The new aryl hydrocarbon receptor antagonist E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one protects against UVB-induced signal transduction. J Invest Dermatol. 2014;134(2):556–559. doi: 10.1038/jid.2013.362
  85. Schade N, Esser C, Krutmann J. Ultraviolet B radiation-induced immunosuppression: molecular mechanisms and cellular alterations. Photochem Photobiol Sci. 2005;4(9):699–708. doi: 10.1039/b418378a
  86. Novák Z, Bérces A, Rontó G, Pállinger E, Dobozy A, Kemény L. Efficacy of different UV-emitting light sources in the induction of T-cell apoptosis. Photochem Photobiol. 2004;79(5):434–439. doi: 10.1562/ra-003r.1
  87. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med. 1997;186(10):1763–1768. doi: 10.1084/jem.186.10.1763
  88. Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583–593.e1–4. doi: 10.1016/j.jaci.2011.05.042
  89. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107(48):20768–20773. doi: 10.1073/pnas.1009201107
  90. Ortiz-Salvador JM, Pérez-Ferriols A. Phototherapy in Atopic Dermatitis. Adv Exp Med Biol. 2017;996:279–286. doi: 10.1007/978-3-319-56017-5_23
  91. Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18(1):64–73. doi: 10.1038/ni.3614
  92. Edamitsu T, Taguchi K, Kobayashi EH, Okuyama R, Yamamoto M. Aryl Hydrocarbon Receptor Directly Regulates Artemin Gene Expression. Mol Cell Biol. 2019;39(20):e00190–e00199. doi: 10.1128/MCB.00190-19
  93. Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853–860. doi: 10.1111/j.1365-2133.2011.10775.x
  94. Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017;137(10):2110–2119. doi: 10.1016/j.jid.2017.05.004
  95. Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89–98.e3. doi: 10.1016/j.jaad.2018.06.047
  96. Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021;84(3):632–638. doi: 10.1016/j.jaad.2020.05.135

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Aryl-carbohydrate receptor (AhR) metabolic effects and tapinarof action points (red arrows)

Download (134KB)
Indexing metadata

Copyright (c) 2023 Gorodnichev P.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».